RecruitingPhase 2NCT07108387
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Studying Giant cell arteritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Sebastian H Unizony, M.D.Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
- Intervention
- Tocilizumab(drug)
- Enrollment
- 78 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2025 – 2030
Study locations (7)
- Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center, Baltimore, Maryland, United States
- Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Boston, Massachusetts, United States
- Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York, United States
- Hospital for Special Surgery, New York: Division of Rheumatology, New York, New York, United States
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07108387 on ClinicalTrials.govOther trials for Giant cell arteritis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07084480Giant Cell Arteritis - Ways to Precision MedicineWuerzburg University Hospital
- RECRUITINGNANCT07001059oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSoundHôpital NOVO
- RECRUITINGNCT06894602Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell ArteritisUniversity Hospital, Brest
- RECRUITINGNCT05749094Optic Nerve Sheath Ultrasound in Giant Cell ArteritisCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- ACTIVE NOT RECRUITINGNCT05703763The Applanation Tonometry in GCA PilotCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- RECRUITINGPHASE2NCT06887062Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)University of Edinburgh
- RECRUITINGNCT06742671Performance of a Fast-track Pathway for Giant Cell Arteritis DiagnosisGroupe Hospitalier de la Rochelle Ré Aunis
- RECRUITINGPHASE2NCT06335888A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel VasculitisInsel Gruppe AG, University Hospital Bern